IL292840A - Methods of treatment with myosin modulator - Google Patents

Methods of treatment with myosin modulator

Info

Publication number
IL292840A
IL292840A IL292840A IL29284022A IL292840A IL 292840 A IL292840 A IL 292840A IL 292840 A IL292840 A IL 292840A IL 29284022 A IL29284022 A IL 29284022A IL 292840 A IL292840 A IL 292840A
Authority
IL
Israel
Prior art keywords
treatment methods
myosin
modulator
myosin modulator
treatment
Prior art date
Application number
IL292840A
Other languages
English (en)
Hebrew (he)
Inventor
Timothy Carlson
Rio Carlos L Del
Jay M Edelberg
Sarah Fernandes
Marcus Patrick Henze
Grace Yanfei Ma
Robert Mcdowell
Matthew Edwards Mealiffe
Amy Sehnert
Marc J Semigran
Kathy L Lampl
David Zhang
Milind Y Desai
Steve Nissen
Liang Fang
Joseph Lambing
Wanying Li
Danielle L Aubele
Brian Edmund Kane
Louis Charles Sehl
Original Assignee
Myokardia Inc
Timothy Carlson
Rio Carlos L Del
Jay M Edelberg
Sarah Fernandes
Marcus Patrick Henze
Grace Yanfei Ma
Robert Mcdowell
Matthew Edwards Mealiffe
Amy Sehnert
Marc J Semigran
Kathy L Lampl
David Zhang
Milind Y Desai
Steve Nissen
Liang Fang
Joseph Lambing
Wanying Li
Danielle L Aubele
Brian Edmund Kane
Louis Charles Sehl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc, Timothy Carlson, Rio Carlos L Del, Jay M Edelberg, Sarah Fernandes, Marcus Patrick Henze, Grace Yanfei Ma, Robert Mcdowell, Matthew Edwards Mealiffe, Amy Sehnert, Marc J Semigran, Kathy L Lampl, David Zhang, Milind Y Desai, Steve Nissen, Liang Fang, Joseph Lambing, Wanying Li, Danielle L Aubele, Brian Edmund Kane, Louis Charles Sehl filed Critical Myokardia Inc
Publication of IL292840A publication Critical patent/IL292840A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL292840A 2019-11-10 2022-05-08 Methods of treatment with myosin modulator IL292840A (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962933517P 2019-11-10 2019-11-10
US201962933970P 2019-11-11 2019-11-11
US201962935922P 2019-11-15 2019-11-15
US202063001473P 2020-03-29 2020-03-29
US202063002302P 2020-03-30 2020-03-30
US202063006701P 2020-04-07 2020-04-07
US202063022573P 2020-05-10 2020-05-10
US202063059143P 2020-07-30 2020-07-30
US202063064450P 2020-08-12 2020-08-12
PCT/US2020/059893 WO2021092598A1 (en) 2019-11-10 2020-11-10 Methods of treatment with myosin modulator

Publications (1)

Publication Number Publication Date
IL292840A true IL292840A (en) 2022-07-01

Family

ID=75849342

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292840A IL292840A (en) 2019-11-10 2022-05-08 Methods of treatment with myosin modulator

Country Status (13)

Country Link
US (1) US20230158027A1 (https=)
EP (1) EP4054588A4 (https=)
JP (1) JP7830321B2 (https=)
KR (1) KR20220113387A (https=)
CN (1) CN114945372A (https=)
AU (1) AU2020378197A1 (https=)
BR (1) BR112022008641A2 (https=)
CA (1) CA3157629A1 (https=)
CL (1) CL2022001217A1 (https=)
IL (1) IL292840A (https=)
MX (1) MX2022005465A (https=)
TW (1) TW202134259A (https=)
WO (1) WO2021092598A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3645002T3 (da) 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
HUE069154T2 (hu) * 2020-01-28 2025-02-28 Assia Chem Ind Ltd A mavakamten szilárd állapotú formái és eljárás elõállításukra
MX2023002024A (es) * 2020-08-28 2023-05-10 Myokardia Inc Métodos de tratamiento con modulador de miosina.
DK4243825T3 (da) 2020-11-12 2025-12-01 Amgen Inc Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper
CN115461052B (zh) * 2020-11-25 2023-12-22 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) * 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
PT4370116T (pt) * 2021-07-16 2025-03-14 Cytokinetics Inc Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva
WO2023102452A1 (en) * 2021-12-02 2023-06-08 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
CN116410143A (zh) * 2021-12-29 2023-07-11 杭州奥默医药股份有限公司 一种多取代脲嘧啶衍生物及其制备方法和应用
CA3248508A1 (en) 2022-04-13 2023-10-19 Assia Chemical Industries Ltd. SOLID STATE FORMS OF MAVACAMTEN AND THEIR PREPARATION METHOD
EP4514355A1 (en) * 2022-04-26 2025-03-05 MyoKardia, Inc. Methods of administering myosin inhibitors
JP2025534288A (ja) 2022-09-26 2025-10-15 エッジワイズ セラピューティクス, インコーポレイテッド 1,4-ジヒドロキナゾリノン化合物およびその使用
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
EP4688756A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
IT202300016653A1 (it) 2023-08-03 2025-02-03 Olon Spa Processo per preparare mavacamten e intermedio di processo.
WO2025046606A1 (en) 2023-08-26 2025-03-06 Micro Labs Limited Granules of mavacamten for oral administration
WO2025096779A2 (en) * 2023-11-01 2025-05-08 Bristol Myers Squibb Company Methods of treatment with a myosin inhibitor using protein levels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908193D0 (en) * 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
EP3399907A4 (en) * 2016-01-04 2019-08-28 Aventusoft, LLC SYSTEM AND METHOD FOR MEASURING HEMODYNAMIC PARAMETERS FROM THE HEADLAPPING SIGNALS
CA3071948A1 (en) * 2017-08-04 2019-02-07 MyoKardia, Inc. Mavacamten for use in the treatment of hypertrophic cardiomyopathy

Also Published As

Publication number Publication date
MX2022005465A (es) 2022-08-08
EP4054588A1 (en) 2022-09-14
CA3157629A1 (en) 2021-05-14
BR112022008641A2 (pt) 2022-09-13
TW202134259A (zh) 2021-09-16
AU2020378197A1 (en) 2022-05-26
KR20220113387A (ko) 2022-08-12
CL2022001217A1 (es) 2023-01-13
WO2021092598A1 (en) 2021-05-14
US20230158027A1 (en) 2023-05-25
JP2023501453A (ja) 2023-01-18
CN114945372A (zh) 2022-08-26
JP7830321B2 (ja) 2026-03-16
EP4054588A4 (en) 2023-12-13

Similar Documents

Publication Publication Date Title
IL292840A (en) Methods of treatment with myosin modulator
EP3994692C0 (en) BINARY COMPUTING CELL IN MEMORY
EP3949904C0 (en) NATURAL VALVE REPAIR DEVICES
IL285771A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
DK3743406T3 (da) Tmem16a modulatorer
EP4203927A4 (en) METHODS OF TREATMENT BY MYOSIN MODULATOR
DK3793885T3 (da) Kædefartøj
EP4069225A4 (en) COMBINATIONS
HUE062866T2 (hu) TREX-1 modulátorok
EP3930851A4 (en) COMBINATION THERAPIES
EP3919491C0 (en) AKT INHIBITOR
EP3767815A4 (en) Multi-level inverter
IL285772A (en) Treatment with p2x3 modulators
EP3967649C0 (en) LIPID NANOPARTICLE
EP3742771C0 (en) M2M SM-SR TO SM-DP NOTIFICATION
EP4003515A4 (en) Klf induced cardiomyogenesis
EP4069241A4 (en) COMBINATIONS
EP4069240A4 (en) ASSOCIATIONS
EP3893762A4 (en) Heart valve repair
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
EP3912517C0 (en) FRAME
EP3973348A4 (en) HEAD MOUNT DISPLAYS
EP3957391C0 (en) AGITATOR
EP4025957C0 (en) ELECTRO-OPTIC MODULATOR
EP4035739A4 (en) HYDROGEL